AdisInsight

Informing drug development in oncology

According to ASCO, the outlook for individuals with cancer is starkly different than 50 years ago. Today, people with some of the most common cancers routinely live for years after being diagnosed, and some cancers previously considered untreatable are responding to recent advances in precision medicine and immunotherapy.  Next-generation treatments are also making their way through clinical trials and they may offer new hope to millions of patients.

AdisInsight is helping researchers in academia, biotech, and pharma keep pace with the rapid development in oncology.  AdisInsight (adisinsight.springer.com) is an integrated database of profiles authored by Springer Nature editors sourced from publicly available information from journals, conferences, trial registries, media releases, company websites, and government filings about pharmaceutical development programs, clinical trial studies, and published individual case safety reports.  Information in AdisInsight is updated daily to keep you informed of the latest information impacting your research.


AdisInsight

Need more info?

Get in touch with us!

Global Drug Pipeline

According to AdisInsight, the global drug pipeline for oncology currently contains 10,950 unique drug programs that are either marketed, in regulatory approval, in clinical development, in preclinical development, or have been discontinued for the treatment of cancer.

New Content Item

A gap analysis of the global drug pipeline reveals a potential unmet medical need for the treatment of Cholangiocarcinoma. Cholangiocarcinoma is considered to be an incurable and rapidly lethal cancer unless both the primary tumor and any metastases can be fully removed by surgery.  There are currently 28 drug programs in clinical development to fill this need.

Read more

 Ivosidenib, is one of the three drugs showing promise in Phase III studies.  It has been granted USA FDA fast track designation and USA FDA orphan drug designation for the treatment of Cholangiocarcinoma.  Below is an example of the AdisInsight drug profile for Ivosidenib.  

Global Clinical Trial Map

AdisInsight shows 33,038 clinical studies investigating pharmaceutical treatment for cancer being conducted in 159 countries.  Some of these studies will be active in either the planning, recruitment, or administration stage while other will be inactive either completed or discontinued.  The clinical trial map shown below aggregates information across all trials researching cancer to show where active clinical studies are taking place at a regional level.

New Content Item

Read more

One of those clinical studies which is taking place in France and USA is a phase 1, multicenter, open-label, dose-escalation, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered Ivosidenib  (AG-120) in subjects with advanced solid tumors, including glioma, with an IDH1 mutation.  This trial sponsored by Agios Pharmaceuticals is currently active and no longer recruiting subjects.  Results from this study were presented at 2017 ASCO Annual Meeting showed morphologic changes suggestive of cellular differentiation.  In the 73 patients studied, Ivosidenib was safe and well-tolerated with a favorable safety profile observed.  Partial response was found in four patients (5%).  Stable disease was demonstrated in 41 patients (56%). The progression free survival observed at 6 and 12 months were 38.5% and 20.7% respectively. The median progression free survival was reported to be 3.8 months.  

View the full profile

View the full profile

Biomarkers for Oncology

Biomarker selection is becoming an essential part of clinical development. Successful use of biomarkers can accelerate the pace of development by predicting drug efficacy more quickly, identifying optima patient populations, and early detection of safety signals.

AdisInsight catalogs 1,001 biomarkers associated with the drugs being studied to treat cancer.  800 of these biomarkers are being used as outcome measures, 445 are being used to detect safety issues, 596 are being used for patient inclusion, and 463 are being used for patient exclusion.  The top 15 biomarkers being used in oncology drug research are shown below.

New Content Item

Organizations Active in Oncology

According to AdisInsight there are 6,100 organizations involved in researching drug development programs for the treatment of cancer.  The table below shows the top 15 organizations ranked according by the number of drug programs in development for cancer. 

Many of these organizations use AdisInsight to inform their strategic decisions as they work to advance drug therapies for the treatment of cancer.  Whether they are identifying unmet clinical needs, monitoring the therapy area landscape, researching innovative disease targets, or planning clinical trial programs, AdisInsight is making drug development more efficient. 

New Content Item

Stay up to date

_
Follow us on Twitter

Here to foster information exchange with the library community

_
Follow us on Facebook

Springer Nature's LibraryZone is a community developed to foster sharing of information with the library community. Enjoy!

_
Connect with us on LinkedIn

Connect with us on LinkedIn and stay up to date with news and development.

_
Sign up for our alerts

News, information on our forthcoming books, author content and discounts.